With the launch of the worldwide vaccination process, there is a rapid pace of vaccine preparation. Meanwhile, China has approved clinical trials of 16 local COVID-19 vaccines, six of which are in the third phase of the vaccine trial, according to a Chinese media report.
Chinese clinical news agency Xinhua on Saturday cited the National Medical Products Administration as saying that the new clinical trial vaccines are based on recombinant proteins, adenovirus vectors, nucleic acids and untouched influenza-virus technology.
The cases, which are constantly active in Mumbai, are dangerous for the state for the next 15 days
These six vaccines are in phase three of the trial, which is the final phase of the trial. China has already given conditional approval to two inactivated COVID-19 vaccines manufactured by state-owned developers Sinofarma and Sinovac Biotech.
As of February 9, China had delivered 40.52 million COVID-19 vaccines to major groups in the country, Xinhua said, referring to a National Health Commission official.